Jump to content

Celiac.com Sponsor (A1):

Celiac.com Sponsor (A1-m):

  • You've found your Celiac Tribe! Join our like-minded, private community and share your story, get encouragement and connect with others.


    • Sign In
    • Sign Up
  • Jefferson Adams
    Jefferson Adams

    Close Relatives of Celiac Patients More Likely to Have "Silent" Celiac Disease

    Reviewed and edited by a celiac disease expert.

    'Silent' celiac disease common in parents, siblings, and children of celiac patients.

    Close Relatives of Celiac Patients More Likely to Have
    Caption: Image: CC BY 2.0--Dizzy-one

    Celiac.com 10/21/2019 - Parents, siblings and children of people with celiac disease are not only more likely to develop the autoimmune disease, they are more likely to develop a "silent" version, which presents few or no obvious symptoms, according to the results of a recent study.

    Because of this, Mayo Clinic researchers are now recommending that these first-degree relatives of celiac patients undergo celiac screening.

    Celiac.com Sponsor (A12):

    Celiac.com Sponsor (A12-m):

    Celiac disease is an autoimmune condition that causes gut damage when those affected consume gluten, a protein in wheat, barley and rye. A strict gluten-free diet is currently the only treatment for celiac disease.

    The study of celiac patients and their families showed that nearly half of close relatives who received celiac blood tests were later diagnosed with the condition. Nearly all of them had atypical symptoms or no symptoms at all. These results are startling, as are the recommendations to test people who show no symptoms, just based on their close relation to known celiac patients. That's unusual, because researchers usually keep their screening efforts restricted to those who show symptoms. 

    Current guidelines call for testing family members when children are diagnosed with celiac disease, but, until now, when adults are diagnosed, called for testing only those close relatives who show symptoms. However, the study shows a clear likelihood of celiac risk in close relatives, which led to the Mayo Clinic's recommendation to extend testing to all close family members of known celiac patients. 

    It's important to diagnosed celiac disease as quickly as possible. Untreated celiac disease patients face an elevated risk of developing other conditions like nutritional deficiencies, anemia, osteoporosis and even lymphoma.

    This is really huge news, as it means that large numbers of people likely have celiac disease without even knowing it. So, if you or your loved ones know anyone with celiac disease, pass along this information. Their immediate family members should probably get screened for celiac disease.

    Hopefully, this study and will trigger more like it, and increase testing of asymptomatic people who are at high risk for undiagnosed celiac disease.

    Read more in the Mayo Clinic Proceedings, online August 22, 2019, and at Reuters.com

    User Feedback

    Recommended Comments

    I find it astounding that this is a new approach.  I was a "silent" celiac sufferer for 50 years, with no symptoms.  At age 50, I became addicted to ice, (the hard form of water type).  My doctor had never encountered a celiac patient and was not familiar with the disease or the symptoms.  He put me through the ringer with multiple blood tests and a colonoscopy when he found that I was severely anemic.  The doctor that administered the colonoscopy wondered why I was back for another one after just a few months after a prior screening with both colonoscopy and endoscopy.  I described the situation, and his nurse assistant immediately asked if I had been checked for "Sprue" in the previous endoscopy.  They hadn't, and did so in that appointment.  The positive blood test came back the same day as the endoscopy positive biopsy.  The doctor called me when I was traveling on business sitting in the hotel room eating a hamburger with a side of pretzels. 

    After a short conversation all the food went in the trash.  Even though my doctor was a celiac "rookie", he did extensive research, and immediately recommended that all of my children, and grand children get the blood screening. (None were symptomatic.)  Keep in mind this was 11 years ago.  2 of my three children, and one of my five grandchildren at the time tested positive. (I have two newer grand kids that have not yet been tested that I know of.  They are my daughter's, who is positive for celiac, so  they may have been.  I will remind her.)

    At any rate, my celiac rookie doctor recognized the potential of the situation and recommend the exact same protocol that is described in the article as "new".

    As an aside, other than the chronic anemia that developed after 50 years, I never had any symptoms severe enough to seek help.  There were others, but I only recognized them after I was diagnosed and researched the topic.  However, after about a year of total gluten free intake, I developed very severe immediate reactions to gluten contamination, mainly severe nausea and vomiting that would last until my system was emptied.  I now carry Zofran, when I travel, (75% of my time).  If I take it when I find out I've been contaminated, (yes, I have restaurants come to my table and tell me they screwed up), or if I develop the sudden intense waves of nausea, sweating, etc., it will keep me from throwing up, but I still feel bad for a few days after.  I highly recommend this to celiac sufferers when they travel. 







    Link to comment
    Share on other sites

    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.

  • About Me

    Jefferson Adams

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,500 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):

    Celiac.com Sponsors (A17-m):

  • Related Articles

    Scott Adams
    Scand J Gastroenterol. 2003 Jul;38(7):727-31.
    Effectiveness of the sorbitol H2 breath test in detecting histological damage among relatives of coeliacs.
    Tursi A, Brandimarte G, Giorgetti GM, Inchingolo celiac disease.
    Dept. of Emergency, L. Bonomo Hospital, Andria (BA), Italy.
    Celiac.com 08/07/2003 - An Italian study conducted by Dr. L. Bonomo and colleagues and published in the July 2003 edition of Scandinavian Journal of Gastroenterology concludes that A significant proportion of coeliacs may be missed if relatives are screened by serology only, while the efficacy of sorbitol H2-BT in screening relatives is confirmed. This study confirms that neither a breath test nor serology can replace intestinal biopsy, which remains the gold standard for the diagnosis of celiac disease, thus confirming the continued importance of performing biopsies for diagnosing celiac disease. The studys goal was to determine the diagnostic capabilities of serological tests (antigliadin (AGA), antiendomysium (EMA) and anti-tissue transglutaminase (anti-tTG)) and sorbitol H2 breath test (H2-BT) in the detection of celiac disease in first-degree relatives. The study screened 111 first-degree relatives of 37 celiac families using both test methods to determine candidates for small-bowel biopsy. First-degree relatives with abnormal test results underwent a small-bowel biopsy, as did those with negative serological and H2 breath test results who had clinical complaints or suspected that they may have celiac disease.
    The biopsy results were expressed using the Marsh classification system, and celiac disease was diagnosed in 49 of the 111 screened relatives of celiacs, or in 44.14%. A breakdown of the results is as follows: 5 showed Marsh IIIc, 8 Marsh IIIb, 16 Marsh IIIa, 13 Marsh II and 7 Marsh I lesions. 19 relatives showed the classical form of celiac disease, 20 showed the sub-clinical form, and 10 showed the silent form. The serological test results indicated an overall positivity of only 36.73%, with strong positive results only in those with severe intestinal damage and Marsh IIIb-c lesions. The sorbitol H2-BT breath test results showed an overall positivity of 83.67%, and showed strong positivity in patients with slight histological damage (Marsh I-IIIa).

    Jefferson Adams
    Celiac.com 11/18/2015 - Researchers have known for some time that first-degree relatives (FDRs) of celiac patients are at high risk for developing the disease, and that prevalence among them varies from 1.6 to 38%. However, not much is known about specific risk levels when the FDR is sister, brother, mother, father, son, or daughter of a celiac patient.
    A team of researchers recently conducted a meta-analysis and calculated pooled prevalence of celiac disease among FDRs, second-degree relatives (SDRs), and specific relations with given celiac patients. The research team included P. Singh, S. Arora, S. Lal, T.A. Strand, G.K. Makharia. They are variously affiliated with the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Max Healthcare, Gurgaon, India; Medical Services Division, Innlandet Hospital Trust, Lillehammer, Norway; and the Department of Gastroenterology and Human Nutrition at the All India Institute of Medical Sciences, New Delhi, India.
    The team searched 2,259 related medical articles, and found 54 articles relevant for their meta-analysis. They defined celiac disease diagnosis using standard biopsy and Marsh criteria. Analysis of their data group showed an overall celiac disease prevalence of 7.5% (95% confidence interval (CI) 6.3%, 8.8%) in 10,252 FDRs and 2.3% (95% CI 1.3%, 3.8%) in 642 SDRs.
    Pooled celiac disease rates were highest in siblings, at 8.9%, followed by offspring, at 7.9%, and parents, at 3.0%.
    A total of 8.4% of female FDRs showed rates of celiac disease compared to 5.2% male FDRs (P=0.047).
    Sisters and daughters of a primary patient had the highest risk of having celiac disease, at 1 in 7 and 1 in 8, respectively), compared to a risk of 1 in 13 in sons, 1 in 16 in brothers, 1 in 32 in mothers, and 1 in 33 in fathers.
    The data also revealed differences in the pooled prevalence of celiac disease in FDRs according to their geographic location.
    Average pooled rates of celiac disease among FDRs is 7.5%, but the actual rate for a given individual varies widely based on their relationship with the primary celiac patient, and is also influenced by gender and geographical location.
    Am J Gastroenterol. 2015 Sep 29. doi: 10.1038/ajg.2015.296.

    Jefferson Adams
    Celiac.com 01/25/2016 - The latest research says that most fail to recommend celiac screening for first degree relatives, although some doctors are better than others.
    In a recent study, researchers tried to get an idea of just how frequently celiac disease patients receive a physician-issued recommendation for first-degree relative screening.
    The research team included Abhik Roy, Colin Smith, Constantine Daskalakis, Kristin Voorhees, Stephanie Moleski, Anthony J DiMarino, David Kastenberg. They are variously associated with the Division of Biostatistics, the Division of Gastroenterology and Hepatology, the Department of Medicine at Thomas Jefferson University, Philadelphia, Pennsylvania, USA, and the National Foundation for Celiac Awareness in Pennsylvania.
    For their study, the research team conducted a 12-question survey assessing whether celiac disease patients receive a physician recommendation to screen first-degree relatives for celiac disease, and the impact of such a recommendation, was validated with outpatients in a university gastroenterology practice, called "University"patients. The 12-question survey was then distributed online to members of the National Foundation for Celiac Awareness (NFCA).
    The team then collected results over 3 months, and used univariate analysis to compare cohort means, and to assess the association between demographic and diagnostic factors and first-degree relative screening recommendations.
    A total of 87 University patients participated in the validation phase. Test-retest reliability of 4 key survey questions was high, with a Kappa coefficient >0.80. The team based its main analyses on data from 677 NFCA and 82 University respondents. Most respondents were female, with an average age of 45 years.
    Nearly 80% of University patients received recommendation for celiac disease screening for first-degree relatives, compared with just 44% of the NFCA respondents (p < 0.001).
    Of patients who did receive a screening recommendation, from either group, 98% percent discussed the recommendation with family members, leading to celiac disease screening in 71% of University patients, and 79% of NFCA respondents, and to a celiac disease diagnosis in 18% of University patients, and 27% of NFCA respondents.
    Physicians commonly fail to mention to their celiac disease patients the importance of screening first-degree family members. Because such screening is so effective, the researchers are suggesting that making such screening recommendations may increase the diagnosis of celiac disease in high risk individuals.
    Journal of Gastroenterology and Hepatology Research, Vol 4, No 12 (2015)

    Jefferson Adams
    Celiac.com 09/02/2019 - A team of researchers recently set out to investigate rates of first-degree relatives (FDRs) with celiac disease detected at screening, and the diagnostic significance of anti-tissue transglutaminase (anti-TTG).
    The research team included Shilpa S. Nellikkal, MBBS, Yamen Hafed, MD, Joseph J. Larson, BS, Joseph A. Murray, MD, and Imad Absah, MD. They are variously affiliated with the the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; the Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and the Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
    Using data from the Mayo Clinic going back to 1983, the team conducted a retrospective study on a group of 104 patients diagnosed with celiac disease and their first-degree relatives.
    The data included demographics, original symptoms, reasons for testing, family history, number of other family members screened, biopsy reports, and results of serologic tests.
    The team screened 360 out of a total of 477 first-degree relatives, finding a total of 160 first-degree relatives who were diagnosed with celiac disease, 62% of whom were female. All diagnosed first-degree relatives had positive anti-TTG titers. 
    They found clinical features in 148 diagnosed first-degree relatives. Just nine of those diagnosed first-degree relatives had classic symptoms, 97 showed non-classic symptoms, and 42 showed no symptoms. Histology reports from 155 first-degree relatives showed 12 with Marsh 1, 77 with Marsh 3a, and 66 with Marsh 3b. 
    The team used levels of anti-TTG greater than or equal to 2.75 of the upper limit of normal to spot first-degree relatives with villous atrophy with 87% sensitivity, 82% specificity, and a positive predictive value of 95%.
    This study of diagnosed celiac patients showed high rates of celiac disease among screened first-degree relatives. Small bowel biopsies revealed that high anti-TTG titers were associated with villous atrophy, irrespective of symptoms.
    Read more at Mayoclinicproceedings.org.

  • Popular Now

  • Create New...